Rakovina Therapeutics Inc. (RKV.V)
- Previous Close
0.0600 - Open
0.0650 - Bid 0.0600 x --
- Ask 0.0650 x --
- Day's Range
0.0600 - 0.0650 - 52 Week Range
0.0400 - 0.2300 - Volume
129,500 - Avg. Volume
415,756 - Market Cap (intraday)
8.403M - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Aug 28, 2025 - Sep 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.40
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.
www.rakovinatherapeutics.comRecent News: RKV.V
View MorePerformance Overview: RKV.V
Trailing total returns as of 6/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RKV.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RKV.V
View MoreValuation Measures
Market Cap
8.40M
Enterprise Value
9.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.36%
Return on Equity (ttm)
-206.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.5M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
75.82k
Total Debt/Equity (mrq)
58.00%
Levered Free Cash Flow (ttm)
-2.74M